| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.GIE.2015.12.036 |
| P8608 | Fatcat ID | release_ior5db2s4bbble4y2qxwru7aru |
| P932 | PMC publication ID | 4912845 |
| P698 | PubMed publication ID | 26772891 |
| P2093 | author name string | Amitabh Chak | |
| Ananya Das | |||
| Bijan Borah | |||
| Herbert Heien | |||
| Prasad G Iyer | |||
| Rajesh Krishnamoorthi | |||
| P2860 | cites work | Nonsteroidal Anti-Inflammatory Drugs and Statins Have Chemopreventative Effects in Patients With Barrett's Esophagus | Q57259827 |
| The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus | Q59705210 | ||
| Risk stratification of Barrett's esophagus: updated prospective multivariate analysis | Q80495357 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| Barrett's esophagus | Q87672139 | ||
| Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus | Q28168285 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas | Q30544316 | ||
| Validation of information recorded on general practitioner based computerised data resource in the United Kingdom | Q33539292 | ||
| Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis | Q33555216 | ||
| Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus | Q33596309 | ||
| Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 | Q33602223 | ||
| Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus | Q33905941 | ||
| Aspirin and cancer risk: a quantitative review to 2011. | Q34269637 | ||
| Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis | Q34324864 | ||
| Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis | Q34352867 | ||
| Barrett's oesophagus: epidemiology, cancer risk and implications for management | Q34375216 | ||
| Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study | Q34471919 | ||
| The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus | Q34542075 | ||
| Type 2 diabetes mellitus and the risk of colorectal cancer | Q34558506 | ||
| Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review | Q34605352 | ||
| Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study | Q35147677 | ||
| Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. | Q35185711 | ||
| Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux | Q35596721 | ||
| Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus | Q35815590 | ||
| Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? | Q36041656 | ||
| Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling | Q36424349 | ||
| Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study | Q36783294 | ||
| Immortal time bias in pharmaco-epidemiology | Q37023172 | ||
| Association of Barrett's esophagus with type II Diabetes Mellitus: results from a large population-based case-control study | Q37398529 | ||
| Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis | Q37416283 | ||
| Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus | Q40603074 | ||
| Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression | Q41027075 | ||
| Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium | Q42147313 | ||
| Immortal time bias in observational studies of drug effects | Q44123059 | ||
| Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus | Q44779979 | ||
| Esophageal adenocarcinoma incidence: are we reaching the peak? | Q45001265 | ||
| Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study | Q45740170 | ||
| Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study | Q46115635 | ||
| Surveillance and survival in Barrett's adenocarcinomas: a population-based study | Q46131128 | ||
| Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma | Q47792603 | ||
| Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. | Q51148501 | ||
| Clinical practice. Barrett's esophagus. | Q51764391 | ||
| Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. | Q52031816 | ||
| Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. | Q53806475 | ||
| Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus | Q57259755 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Barrett's esophagus | Q808892 |
| esophageal carcinoma | Q18553999 | ||
| P304 | page(s) | 40-46.e7 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | Gastrointestinal Endoscopy | Q15724481 |
| P1476 | title | Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort | |
| P478 | volume | 84 |
| Q93202298 | A phase I pilot study evaluating the beneficial effects of black raspberries in patients with Barrett's esophagus |
| Q33661718 | Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies |
| Q39097596 | Barrett's esophagus: diagnosis and management |
| Q40396082 | Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort |
| Q57433696 | Environmentally Induced Alterations in the Epigenome Affecting Obesity and Cancer in Minority Populations |
| Q93083327 | Interactive decision support for esophageal adenocarcinoma screening and surveillance |
| Q88528275 | Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile? |
| Q90408776 | Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma |
| Q39425042 | Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma. |
| Q38937421 | Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus |
| Q37227732 | The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival. |
Search more.